Ltb4r1 inhibitor: A pivotal insulin sensitizer?

Saeed Esmaili; Jacob George

doi:10.1016/j.tem.2015.03.007

Ltb4r1 inhibitor: A pivotal insulin sensitizer?

Trends Endocrinol Metab. 2015 May;26(5):221-2. doi: 10.1016/j.tem.2015.03.007. Epub 2015 Apr 7.

Authors

Saeed Esmaili¹, Jacob George²

Affiliations

¹ Storr Liver Centre, Westmead Millennium Institute and Westmead Hospital, University of Sydney, Sydney, New South Wales 2145, Australia; Liver and Pancreatobiliary Diseases Research Centre, Digestive Disease Research Institute, Shariati Hospital, Tehran university of Medical Sciences, Tehran, Iran. Electronic address: saeed.esmaili@sydney.edu.au.
² Storr Liver Centre, Westmead Millennium Institute and Westmead Hospital, University of Sydney, Sydney, New South Wales 2145, Australia. Electronic address: jacob.george@sydney.edu.au.

PMID: 25858788
DOI: 10.1016/j.tem.2015.03.007

Abstract

The potent chemokine leukotriene B4 (LTB4) is increased in obesity, and is associated with insulin resistance. A recent article shows that inhibition of its receptor LTB4 receptor 1 (Ltb4r1) improves insulin sensitivity in muscle and liver via cytokine-independent mechanisms, and reduces proinflammatory immune cell infiltration in the adipose tissue.

Keywords: inflammation; insulin sensitivity; leukotriene B4; leukotriene B4 receptor; obesity.

Publication types

Comment

MeSH terms

Animals
Hepatocytes / immunology*
Insulin Resistance / immunology*
Leukotriene B4 / immunology*
Macrophages / immunology*
Muscle Fibers, Skeletal / immunology*
Obesity / immunology*
Receptors, Leukotriene B4 / immunology*

Substances

Receptors, Leukotriene B4
Leukotriene B4